Qualigen Therapeutics, Inc. (AIXC)
NASDAQ: AIXC · Real-Time Price · USD
2.840
0.00 (0.00%)
Nov 19, 2025, 3:08 PM EST - Market open
Qualigen Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| - | - | - | - | 5.65 | 4.31 | Upgrade | |
Revenue Growth (YoY) | - | - | - | - | 31.29% | -22.52% | Upgrade |
Cost of Revenue | 0.02 | 0.02 | 0.16 | 4.49 | 16.05 | 7.19 | Upgrade |
Gross Profit | -0.02 | -0.02 | -0.16 | -4.49 | -10.4 | -2.88 | Upgrade |
Selling, General & Admin | 6.8 | 4.2 | 6.1 | 10.27 | 12.27 | 8.42 | Upgrade |
Research & Development | 0.09 | 1.17 | 5.05 | - | - | - | Upgrade |
Operating Expenses | 6.89 | 5.38 | 11.15 | 10.27 | 12.27 | 8.42 | Upgrade |
Operating Income | -6.91 | -5.4 | -11.3 | -14.76 | -22.66 | -11.3 | Upgrade |
Interest Expense | -0.74 | -0.91 | -1.52 | -0.03 | - | -0.14 | Upgrade |
Interest & Investment Income | 0.53 | 0.13 | - | - | 0.04 | - | Upgrade |
Other Non Operating Income (Expenses) | 0.47 | 0.61 | 2.07 | 0.91 | 4.73 | -8.05 | Upgrade |
EBT Excluding Unusual Items | -6.65 | -5.57 | -10.76 | -13.89 | -17.89 | -19.49 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -0.02 | - | - | - | Upgrade |
Asset Writedown | - | - | - | - | - | -1.38 | Upgrade |
Other Unusual Items | -0.22 | -0.58 | -1.7 | - | - | 0.45 | Upgrade |
Pretax Income | -7.22 | -6.15 | -12.48 | -13.89 | -17.89 | -20.42 | Upgrade |
Income Tax Expense | 0.01 | 0.01 | -0 | 0.01 | 0.01 | -0 | Upgrade |
Earnings From Continuing Operations | -7.23 | -6.16 | -12.48 | -13.89 | -17.9 | -20.42 | Upgrade |
Earnings From Discontinued Operations | - | -0.1 | -0.94 | -4.75 | - | - | Upgrade |
Net Income to Company | -7.23 | -6.26 | -13.42 | -18.64 | -17.9 | -20.42 | Upgrade |
Net Income | -7.23 | -6.26 | -13.42 | -18.64 | -17.9 | -20.42 | Upgrade |
Preferred Dividends & Other Adjustments | 0.87 | 0.09 | - | - | - | - | Upgrade |
Net Income to Common | -8.09 | -6.35 | -13.42 | -18.64 | -17.9 | -20.42 | Upgrade |
Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | 654.38% | 256.40% | 32.09% | 30.91% | 102.67% | 158.37% | Upgrade |
EPS (Basic) | -5.61 | -17.55 | -132.25 | -242.69 | -305.05 | -705.37 | Upgrade |
EPS (Diluted) | -5.61 | -17.55 | -132.25 | -242.79 | -305.05 | -705.37 | Upgrade |
Free Cash Flow | -7.1 | -6.33 | -10.3 | -13.25 | -14.87 | -9.97 | Upgrade |
Free Cash Flow Per Share | -4.92 | -17.50 | -101.57 | -172.48 | -253.37 | -344.25 | Upgrade |
Gross Margin | - | - | - | - | -183.87% | -66.87% | Upgrade |
Operating Margin | - | - | - | - | -400.85% | -262.49% | Upgrade |
Profit Margin | - | - | - | - | -316.56% | -474.16% | Upgrade |
Free Cash Flow Margin | - | - | - | - | -262.93% | -231.41% | Upgrade |
EBITDA | - | -5.4 | -11.3 | -14.75 | -22.55 | -11.16 | Upgrade |
EBITDA Margin | - | - | - | - | - | -259.27% | Upgrade |
D&A For EBITDA | - | 0 | 0 | 0.01 | 0.11 | 0.14 | Upgrade |
EBIT | -6.91 | -5.4 | -11.3 | -14.76 | -22.66 | -11.3 | Upgrade |
EBIT Margin | - | - | - | - | - | -262.49% | Upgrade |
Revenue as Reported | - | - | - | - | 5.65 | 4.31 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.